Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
MT-303 by Myeloid Therapeutics for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval
MT-303 is under clinical development by Myeloid Therapeutics and currently in Phase I for Metastatic Hepatocellular Carcinoma (HCC). According to...